Literature DB >> 18553162

Delayed hematological recovery following autologous transplantation utilizing peripheral blood stem cells harvested after treatment with arsenic trioxide.

Toshimitsu Ueki1, Kazuteru Ohashi, Minako Jinta, Yoshiki Okuyama, Kiyoshi Hiruma, Hideki Akiyama, Hisashi Sakamaki.   

Abstract

We describe herein two cases of delayed hematological recovery (DHR) following autologous peripheral blood stem cell transplantation (auto-PBSCT) using cells harvested during second molecular remission after treatment with arsenic trioxide (As(2)O(3)). Current therapeutic strategies with As(2)O(3) plus auto-PBSCT might be hampered by potential mechanisms of DHR. Our observations highlight the need for study of the real effects of As(2)O(3) on the kinetics of normal hematopoietic engraftment following auto-PBSCT.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18553162     DOI： 10.1007/s12253-008-9049-5

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN： 1219-4956            Impact factor:   3.201


  10 in total

1.  Successful unrelated bone marrow transplantation after arsenic trioxide treatment in a patient with relapsed acute promyelocytic leukemia.

Authors:  Michiaki Mikoshiba; Kazuteru Ohashi; Naoko Takei; Yoshiki Okuyama; Yasuharu Maeda; Kiyoshi Hiruma; Hideki Akiyama; Osamu Fukuhara; Akihiro Takeshita; Hisashi Sakamaki
Journal:  Int J Hematol       Date:  2002-01       Impact factor: 2.490

2.  CD34(+) cell subsets and long-term culture colony-forming cells evaluated on both autologous and normal bone marrow stroma predict long-term hematopoietic engraftment in patients undergoing autologous peripheral blood stem cell transplantation.

Authors:  F Lanza; D Campioni; S Moretti; M Dominici; M Punturieri; E Focarile; S Pauli; M Dabusti; A Tieghi; M Bacilieri; C Scapoli; C De Angeli; L Galluccio; G Castoldi
Journal:  Exp Hematol       Date:  2001-12       Impact factor: 3.084

Review 3.  Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies.

Authors:  Dan Douer; Martin S Tallman
Journal:  J Clin Oncol       Date:  2005-04-01       Impact factor: 44.544

4.  Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients.

Authors:  C Niu; H Yan; T Yu; H P Sun; J X Liu; X S Li; W Wu; F Q Zhang; Y Chen; L Zhou; J M Li; X Y Zeng; R R Yang; M M Yuan; M Y Ren; F Y Gu; Q Cao; B W Gu; X Y Su; G Q Chen; S M Xiong; T D Zhang; S Waxman; Z Y Wang; Z Chen; J Hu; Z X Shen; S J Chen
Journal:  Blood       Date:  1999-11-15       Impact factor: 22.113

5.  Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: a retrospective analysis of the European acute promyelocytic leukemia group.

Authors:  S de Botton; A Fawaz; S Chevret; H Dombret; X Thomas; M Sanz; A Guerci; J San Miguel; J de la Serna; A M Stoppa; O Reman; A Stamatoulas; M Fey; J Y Cahn; J J Sotto; J H Bourhis; A Parry; C Chomienne; L Degos; P Fenaux
Journal:  J Clin Oncol       Date:  2004-11-08       Impact factor: 44.544

6.  Hematopoietic recovery in cancer patients after transplantation of autologous peripheral blood CD34+ cells or unmanipulated peripheral blood stem and progenitor cells.

Authors:  Y Beguin; E Baudoux; B Sautois; V Fraipont; N Schaaf-Lafontaine; M Pereira; J M Paulus; D Sondag; G Fillet
Journal:  Transfusion       Date:  1998-02       Impact factor: 3.157

7.  Melphalan-total body irradiation and autologous bone marrow transplantation for adult acute leukemia beyond first remission.

Authors:  J Mehta; R Powles; S Singhal; C Horton; D Tait; J Treleaven
Journal:  Bone Marrow Transplant       Date:  1996-07       Impact factor: 5.483

8.  Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide.

Authors:  S L Soignet; P Maslak; Z G Wang; S Jhanwar; E Calleja; L J Dardashti; D Corso; A DeBlasio; J Gabrilove; D A Scheinberg; P P Pandolfi; R P Warrell
Journal:  N Engl J Med       Date:  1998-11-05       Impact factor: 91.245

Review 9.  Arsenic trioxide (trisenox) therapy for acute promyelocytic leukemia in the setting of hematopoietic stem cell transplantation.

Authors:  Dan Douer; Wendy Hu; Sergio Giralt; Michael Lill; John DiPersio
Journal:  Oncologist       Date:  2003

10.  The recent JALSG study for newly diagnosed patients with acute promyelocytic leukemia (APL).

Authors:  R Ohno; N Asou
Journal:  Ann Hematol       Date:  2004       Impact factor: 3.673
  10 in total
  3 in total

Review 1.  Has Hematopoietic Stem Cell Transplantation a Role in the Treatment of Children and Adolescents with Acute Promyelocytic Leukemia?

Authors:  Anna Maria Testi; Paolo Musiu; Maria Luisa Moleti; Saveria Capria; Walter Barberi
Journal:  Mediterr J Hematol Infect Dis       Date:  2022-05-01       Impact factor: 3.122

2.  Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis.

Authors:  G N Mannis; A C Logan; A D Leavitt; M Yanada; J Hwang; R L Olin; L E Damon; C Andreadis; W Z Ai; K M Gaensler; C C Greene; N K Gupta; L D Kaplan; A Mahindra; Y Miyazaki; T Naoe; S Ohtake; P H Sayre; C C Smith; J M Venstrom; J L Wolf; L Caballero; N Emi; T G Martin
Journal:  Bone Marrow Transplant       Date:  2014-09-22       Impact factor: 5.483

Review 3.  Role of Hematopoietic Stem Cell Transplantation in Acute Promyelocytic Leukemia.

Authors:  Jaime Sanz; Pau Montesinos; Miguel A Sanz
Journal:  Front Oncol       Date:  2021-03-18       Impact factor: 6.244
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.